Adaptive Phage Therapeutics

Adaptive Phage Therapeutics (APT) is a clinical-stage company dedicated to developing therapies for multidrug-resistant infections. APT's PhageBank™ approach utilizes an ever-expanding library of bacteriophages (phages) that collectively provide evergreen broad-spectrum and microbial coverage. PhageBank™ phages are matched through APT's proprietary phage susceptibility test, conducted in collaboration with Mayo Clinic Laboratories, enabling global commercialization.